TY - JOUR
T1 - Assessment of Clinical Outcomes among Children and Adolescents Hospitalized with COVID-19 in 6 Sub-Saharan African Countries
AU - African Forum for Research and Education in Health (AFREhealth) COVID-19 Research Collaboration on Children and Adolescents
AU - Nachega, Jean B.
AU - Sam-Agudu, Nadia A.
AU - MacHekano, Rhoderick N.
AU - Rabie, Helena
AU - Van Der Zalm, Marieke M.
AU - Redfern, Andrew
AU - Dramowski, Angela
AU - O'Connell, Natasha
AU - Pipo, Michel Tshiasuma
AU - Tshilanda, Marc B.
AU - Byamungu, Liliane Nsuli
AU - Masekela, Refiloe
AU - Jeena, Prakash Mohan
AU - Pillay, Ashendri
AU - Gachuno, Onesmus W.
AU - Kinuthia, John
AU - Ishoso, Daniel Katuashi
AU - Amoako, Emmanuella
AU - Agyare, Elizabeth
AU - Agbeno, Evans K.
AU - Martyn-Dickens, Charles
AU - Sylverken, Justice
AU - Enimil, Anthony
AU - Jibril, Aishatu Mohammed
AU - Abdullahi, Asara M.
AU - Amadi, Oma
AU - Umar, Umar Mohammed
AU - Sigwadhi, Lovemore Nyasha
AU - Hermans, Michel P.
AU - Otokoye, John Otshudiema
AU - Mbala-Kingebeni, Placide
AU - Muyembe-Tamfum, Jean Jacques
AU - Zumla, Alimuddin
AU - Sewankambo, Nelson K.
AU - Aanyu, Hellen Tukamuhebwa
AU - Musoke, Philippa
AU - Suleman, Fatima
AU - Adejumo, Prisca
AU - Noormahomed, Emilia V.
AU - Deckelbaum, Richard J.
AU - Fowler, Mary Glenn
AU - Tshilolo, Léon
AU - Smith, Gerald
AU - Mills, Edward J.
AU - Umar, Lawal W.
AU - Siedner, Mark J.
AU - Kruger, Mariana
AU - Rosenthal, Philip J.
AU - Mellors, John W.
AU - Mofenson, Lynne M.
N1 - Funding Information:
reported receiving grants from the Fogarty International Center at the National Institutes of Health (NIH) during the conduct of the study. Dr Sam-Agudu reported receiving grants from the African Forum for Research and Education in Health (AFREhealth) during the conduct of the study. Dr Rabie reported receiving grants from AFREhealth during the conduct of the study. Dr Byamungu reported receiving grants from the Fogarty International Center at the NIH during the conduct of the study. Dr Amoako reported receiving personal fees from AFREhealth during the conduct of the study. Dr Agbeno reported receiving personal fees from AFREhealth during the conduct of the study. Dr Martyn-Dickens reported receiving grants from AFREhealth during the conduct of the study. Dr Enimil reported receiving personal fees from Komfo Anokye Teaching Hospital during the conduct of the study. Dr Jibril reported receiving personal fees from AFREhealth during the conduct of the study. Dr Abdullahi reported receiving personal fees from AFREhealth during the conduct of the study. Dr Amadi reported receiving grants from AFREhealth during the conduct of the study. Dr U. Umar reported receiving grants from AFREhealth during the conduct of the study. Dr Aanyu reported receiving grants from AFREhealth during the conduct of the study. Dr Musoke reported receiving grants from AFREhealth during the conduct of the study. Dr L. Umar reported receiving grants from AFREhealth during the conduct of the study and grants from the Fogarty International Center at the NIH (directed to AFREhealth via the Makerere University Infectious Disease Institute) outside the submitted work. Dr Mellors reported receiving grants from Gilead Sciences (via the University of Pittsburgh), Janssen Pharmaceuticals (via the University of Pittsburgh), the NIH (via the University of Pittsburgh), and the US Agency for International Development (via the University of Pittsburgh); personal fees from Accelevir Diagnostics, Gilead Sciences, Merck & Co, the University of Pittsburgh, and Yufan Biotechnologies; owning shares in Abound Bio, Cocrystal Pharma, and Infectious Disease Connect; and serving as president and chief executive officer of Abound Bio, a scientific advisory board member of Gilead Sciences, and an advisor for Infectious Disease Connect outside the submitted work. Dr Muyembe-Tamfum reported receiving grants from the National Institute of Biomedical Research, Democratic Republic of the Congo during the conduct of the study and outside the submitted work. No other disclosures were reported.
Publisher Copyright:
© 2022 Nachega JB et al.
PY - 2022/3
Y1 - 2022/3
N2 - Importance: Little is known about COVID-19 outcomes among children and adolescents in sub-Saharan Africa, where preexisting comorbidities are prevalent. Objective: To assess the clinical outcomes and factors associated with outcomes among children and adolescents hospitalized with COVID-19 in 6 countries in sub-Saharan Africa. Design, Setting, and Participants: This cohort study was a retrospective record review of data from 25 hospitals in the Democratic Republic of the Congo, Ghana, Kenya, Nigeria, South Africa, and Uganda from March 1 to December 31, 2020, and included 469 hospitalized patients aged 0 to 19 years with SARS-CoV-2 infection. Exposures: Age, sex, preexisting comorbidities, and region of residence. Main Outcomes and Measures: An ordinal primary outcome scale was used comprising 5 categories: (1) hospitalization without oxygen supplementation, (2) hospitalization with oxygen supplementation, (3) ICU admission, (4) invasive mechanical ventilation, and (5) death. The secondary outcome was length of hospital stay. Results: Among 469 hospitalized children and adolescents, the median age was 5.9 years (IQR, 1.6-11.1 years); 245 patients (52.4%) were male, and 115 (24.5%) had comorbidities. A total of 39 patients (8.3%) were from central Africa, 172 (36.7%) from eastern Africa, 208 (44.3%) from southern Africa, and 50 (10.7%) from western Africa. Eighteen patients had suspected (n = 6) or confirmed (n = 12) multisystem inflammatory syndrome in children. Thirty-nine patients (8.3%) died, including 22 of 69 patients (31.9%) who required intensive care unit admission and 4 of 18 patients (22.2%) with suspected or confirmed multisystem inflammatory syndrome in children. Among 468 patients, 418 (89.3%) were discharged, and 16 (3.4%) remained hospitalized. The likelihood of outcomes with higher vs lower severity among children younger than 1 year expressed as adjusted odds ratio (aOR) was 4.89 (95% CI, 1.44-16.61) times higher than that of adolescents aged 15 to 19 years. The presence of hypertension (aOR, 5.91; 95% CI, 1.89-18.50), chronic lung disease (aOR, 2.97; 95% CI, 1.65-5.37), or a hematological disorder (aOR, 3.10; 95% CI, 1.04-9.24) was associated with severe outcomes. Age younger than 1 year (adjusted subdistribution hazard ratio [asHR], 0.48; 95% CI, 0.27-0.87), the presence of 1 comorbidity (asHR, 0.54; 95% CI, 0.40-0.72), and the presence of 2 or more comorbidities (asHR, 0.26; 95% CI, 0.18-0.38) were associated with reduced rates of hospital discharge. Conclusions and Relevance: In this cohort study of children and adolescents hospitalized with COVID-19 in sub-Saharan Africa, high rates of morbidity and mortality were observed among infants and patients with noncommunicable disease comorbidities, suggesting that COVID-19 vaccination and therapeutic interventions are needed for young populations in this region.
AB - Importance: Little is known about COVID-19 outcomes among children and adolescents in sub-Saharan Africa, where preexisting comorbidities are prevalent. Objective: To assess the clinical outcomes and factors associated with outcomes among children and adolescents hospitalized with COVID-19 in 6 countries in sub-Saharan Africa. Design, Setting, and Participants: This cohort study was a retrospective record review of data from 25 hospitals in the Democratic Republic of the Congo, Ghana, Kenya, Nigeria, South Africa, and Uganda from March 1 to December 31, 2020, and included 469 hospitalized patients aged 0 to 19 years with SARS-CoV-2 infection. Exposures: Age, sex, preexisting comorbidities, and region of residence. Main Outcomes and Measures: An ordinal primary outcome scale was used comprising 5 categories: (1) hospitalization without oxygen supplementation, (2) hospitalization with oxygen supplementation, (3) ICU admission, (4) invasive mechanical ventilation, and (5) death. The secondary outcome was length of hospital stay. Results: Among 469 hospitalized children and adolescents, the median age was 5.9 years (IQR, 1.6-11.1 years); 245 patients (52.4%) were male, and 115 (24.5%) had comorbidities. A total of 39 patients (8.3%) were from central Africa, 172 (36.7%) from eastern Africa, 208 (44.3%) from southern Africa, and 50 (10.7%) from western Africa. Eighteen patients had suspected (n = 6) or confirmed (n = 12) multisystem inflammatory syndrome in children. Thirty-nine patients (8.3%) died, including 22 of 69 patients (31.9%) who required intensive care unit admission and 4 of 18 patients (22.2%) with suspected or confirmed multisystem inflammatory syndrome in children. Among 468 patients, 418 (89.3%) were discharged, and 16 (3.4%) remained hospitalized. The likelihood of outcomes with higher vs lower severity among children younger than 1 year expressed as adjusted odds ratio (aOR) was 4.89 (95% CI, 1.44-16.61) times higher than that of adolescents aged 15 to 19 years. The presence of hypertension (aOR, 5.91; 95% CI, 1.89-18.50), chronic lung disease (aOR, 2.97; 95% CI, 1.65-5.37), or a hematological disorder (aOR, 3.10; 95% CI, 1.04-9.24) was associated with severe outcomes. Age younger than 1 year (adjusted subdistribution hazard ratio [asHR], 0.48; 95% CI, 0.27-0.87), the presence of 1 comorbidity (asHR, 0.54; 95% CI, 0.40-0.72), and the presence of 2 or more comorbidities (asHR, 0.26; 95% CI, 0.18-0.38) were associated with reduced rates of hospital discharge. Conclusions and Relevance: In this cohort study of children and adolescents hospitalized with COVID-19 in sub-Saharan Africa, high rates of morbidity and mortality were observed among infants and patients with noncommunicable disease comorbidities, suggesting that COVID-19 vaccination and therapeutic interventions are needed for young populations in this region.
UR - http://www.scopus.com/inward/record.url?scp=85123353720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123353720&partnerID=8YFLogxK
U2 - 10.1001/jamapediatrics.2021.6436
DO - 10.1001/jamapediatrics.2021.6436
M3 - Article
C2 - 35044430
AN - SCOPUS:85123353720
SN - 2168-6203
VL - 176
SP - E216436
JO - American Journal of Diseases of Children
JF - American Journal of Diseases of Children
IS - 3
ER -